Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin

Journal of Biochemistry

Volumn 144, Issue 2, 2008, Pages 207-213

  Tan, Haining ^a   Yang, Shenglin ^a   Feng, You ^a   Liu, Chunhui ^a   Cao, Jichao ^a   Mu, Guoying ^a   Wang, Fengshan ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Chemical modification; Endostatin; Low molecular weight heparin; Polyethylene glycol; Stability; Structure

Indexed keywords

ENDOSTATIN; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL;

ARTICLE; CHEMICAL MODIFICATION; CIRCULAR DICHROISM; DRUG STABILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY;

ANGIOGENESIS INHIBITORS; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOSTATINS; HEAT; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; PROTEIN STRUCTURE, SECONDARY; SOLUBILITY;

EID: 48749113882     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvn060     Document Type: Article

References (23)

1. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiognesis and tumor growth. Cell 88, 277-285
2. Addison, C.L., Nor, J.E., Zhao, H., Linn, S.A., Polverini, P.J., and Delaney, C.E. (2005) The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent. BMC Cell Biol. 6, 38-57
3. Marneros, A.G. and Olsen, B.R. (2005) Physiological role of collagen XVIII and endostatin. FASEB J. 19, 716-728
4. Sun, Y., Wang, J., Liu, Y., Song, X., Zhang, Y., Li, K., Zhu, Y., Zhou, Q., You, L., and Yao, C. (2005) Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. (Meeting Abstract) 23, 7138
5. Folkman, J. (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp. Cell Res. 312, 594-607
6. Herbst, R.S., Hess, K.R., Tran, H.T., Tseng, J.E., Mullani, N.A., Charnsangavej, C., Madden, T., Davis, D.W., McConkey, D.J., O'Reilly, M.S., Ellis, L.M., Pluda, J., Hong, W.K., and Abbruzzese, J.L. (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20, 3792-3803
7. Abdollahi, A., Hlatky, L., and Huber, P.E. (2005) Endostatin: the logic of antiangiogenic therapy. Drug Resist. Updat. 8, 59-74
8. Tsubery, H., Mironchik, M., Fridkin, M., and Shechter, Y. (2004) Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J. Biol. Chem. 279, 38118-38124
9. Anderson, J.A., Fredenburgh, J.C., Stafford, A.R., Guo, Y.S., Hirsh, J., Ghazarossian, V., and Weitz, J.I. (2001) Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. J. Biol. Chem. 276, 9755-9761
10. Pyatak, P.S., Abuchowski, A., and Davis, F.F. (1980) Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. Res. Commun. Chem. Pathol. Pharmacol. 29, 113-127
11. Abuchowski, A., van Es, T., Palzuk, N.C., and Davis, F.F. (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252, 3578-3581
12. Tam, S.C., Blumenstein, J., and Wong, J.T. (1976) Soluble dextran-hemoglobi complex as a potential blood substitute. Proc. Natl Acad. Sci. USA 73, 3128-3131
13. Zhang, H.W., Wang, F.S., Shao, W., Zheng, X.L., Qi., J.Z., Cao, J.C., and Zhang, T.M. (2006) Characterization and stability investigation of cu, zn-superoxide dismutase covalently modified by low molecular weight heparin. Biochemistry (Moscow) 71, S96-S100
14. Li, J.W., Xiao, N.G., Yu, R.Y., Yuan, M.X., Chen, L.R., Chen, Y.H., and Chen, L.T. (2000) Experimental Principles and Methods of Biochemistry, pp. 189-223, Peking University Publishers, Beijing
15. Habeeb, A.F. (1966) Determination of free amina groups in protein by trintrobenzennesulfonic acid. Anal. Biochem. 14, 328-336
16. Situ, Z.Q. and Wu, J.Z. (2004) Cell Culture, pp. 250-252, Shijie book publishing company, Xi'an
17. Bagley, R.G., Walter-Yohrling, J., Cao, X., Weber, W., Simons, B., Cook, B.P., Chartrand, S.D., Wang, C., Madden, S.L., and Teicher, B.A. (2003) Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res. 63, 5866-5873
18. Byler, D.M. and Susi, H. (1986) Examination of the secondary structure of proteins by deconvolved FTIR spectra. Biopolymers 25, 469-487
19. Sasaki, T., Fukai, N., Mann, K., Goring, W., Olsen, B.R., and Timpl, R. (1998) Structure, function and tissue forms of the Cterminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 17, 4249-4256
20. Inada, Y., Furukawa, M., Sasaki, H., Kodera, Y., Hiroto, M, Nishimura, H., and Matsushima, A. (1995) Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol. 13, 86-91
21. Supinski, G.S. and Callahan, L.A. (2006) Polyethylene glycol-superoxide dismutase prevents endotoxin-induced cardiac dysfunction. Am. J. Respir. Crit. Care. Med. 173, 1240-1247
22. Norrby, K. (2006) Low-molecular-weight heparins and angiogenesis. APMIS 114, 79-102
23. Hohenester, E., Sasaki, T., Olsen, B.R., and Timpl, R. (1998) Crystal structure of the angiogenesis inhibitor endostatin at 1.5A resolution. EMBO J. 17, 1656-1664